Autoimmune-induced glutamatergic receptor dysfunctions: Conceptual and psychiatric practice implications

European Neuropsychopharmacology

Volumn 23, Issue 12, 2013, Pages 1659-

  Rosenthal Simons, Ayelet ^a   Durrant, Andrea R ^b   Heresco Levy, Uriel ^a,b  

^a HEBREW UNIVERSITY   (Israel)

^b HERZOG HOSPITAL   (Israel)

Author keywords

Depression; Encephalitis; Glutamate; Movement disorders; NMDAR; Schizophrenia

Indexed keywords

ALPHA AMINO 3 HYDROXY 5 METHYL 4 ISOXAZOLEPROPIONIC ACID; AMPA RECEPTOR; BENZATROPINE; GLUTAMIC ACID; LITHIUM; METABOTROPIC RECEPTOR; N METHYL DEXTRO ASPARTIC ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; PHENCYCLIDINE; VALPROIC ACID;

ANTI N METHYL D ASPARTATE RECEPTOR ENCEPHALITIS; AUTOIMMUNE DISEASE; AUTOIMMUNE INDUCED GLUTAMATERGIC RECEPTOR DYSFUNCTION; ENCEPHALITIS; HUMAN; IMMUNE RESPONSE; MAJOR DEPRESSION; MENTAL DISEASE; MOOD; MOTOR DYSFUNCTION; NEUROTRANSMISSION; OCULOGYRIC CRISIS; OPISTHOTONUS; PATHOGENESIS; PRIORITY JOURNAL; PSYCHIATRY; REVIEW; SCHIZOPHRENIA; SUICIDAL IDEATION; TONIC CLONIC SEIZURE;

EID: 84887608193     PISSN: 0924977X     EISSN: 18737862     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2013.05.008     Document Type: Review

References (98)

1. Anwyl R. Metabotropic glutamate receptors: electrophysiological properties and role in plasticity. Brain Res. Rev. 1999, 29:83-120.
2. Bataller L., Kleopa K.A., Wu G.F., Rossi J.E., Rosenfeld M.R., Dalmau J. Autoimmune limbic encephalitis in 39 patients: immunophenotypes and outcomes. J. Neurol. Neurosurg. Psychiatry 2007, 78:381-385.
3. Beneyto M., Meador-Woodruff J.H. Lamina-specific abnormalities of NMDA receptor-associated postsynaptic protein transcripts in the prefrontal cortex in schizophrenia and bipolar disorder. Neuropsychopharmacology 2008, 33:2175-2186.
4. Carr I. The Ophelia syndrome: memory loss in Hodgkin's disease. Lancet 1982, 319:844-845.
5. Chapman M.R., Vause H.E. Anti-NMDA receptor encephalitis: diagnosis, psychiatric presentation, and treatment. Am. J. Psychiatry 2011, 168:245-251.
6. Corsellis J.A., Goldberg G.J., Norton A.R. "Limbic encephalitis" and its association with carcinoma. Brain 1968, 91:481-496.
7. Cotman C.W., Monaghan D.T., Ganong A.H. Excitatory amino acid neurotransmission: NMDA receptors and Hebb-type synaptic plasticity. Annu. Rev. Neurosci. 1988, 11:61-80.
8. Coyle J.T., Balu D., Benneyworth M., Basu A., Roseman A. Beyond the dopamine receptor: novel therapeutic targets for treating schizophrenia. Dialogues Clin. Neurosci. 2010, 12:359-382.
9. Coyle J.T. The glutamatergic dysfunction hypothesis for schizophrenia. Harv. Rev. Psychiatry 1996, 3:241-253.
10. Dale R.C., Irani S.R., Brilot F., Pillai S., Webster R., Gill D., Lang B., Vincent A. N-methyl-d-aspartate receptor antibodies in pediatric dyskinetic encephalitis lethargica. Ann. Neurol. 2009, 66:704-709.
11. Dalmau J., Lancaster E., Martinez-Hernandez E., Rosenfeld M.R., Balice-Gordon R. Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis. Lancet Neurol. 2011, 10:63-74.
12. Dalmau J., Rosenfeld M.R. Paraneuroplastic syndromes of the CNS. Lancet Neurol. 2008, 7:327-340.
13. Dalmau J., Gleichman A.J., Hughes E.G., Rossi J.E., Peng X., Lai M., Dessain S.K., Rosenfeld M.R., Balice-Gordon R., Lynch D.R. Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies. Lancet Neurol. 2008, 7:1091-1098.
14. Dalmau J., Tüzün E., Wu H.Y., Masjuan J., Rossi J.E., Voloschin A., Baehring J.M., Shimazaki H., Koide R., King D., Mason W., Sansing I.H., Dichter M.A., Rosenfeld M.R., Lynch D.R. Paraneoplastic anti-N-methyl-d-aspartate receptor encephalitis associated with ovarian teratoma. Ann. Neurol. 2007, 61:25-36.
15. Dalmau J., Graus F., Rosenblum M.K., Posner J.B. Anti-Hu-associated paraneoplastic encephalomyelitis/sensory neuronopathy. A clinical study of 71 patients. Medicine 1992, 71:59-72.
16. Dambinova S.A., Khounteev G.A., Izykenova G.A., Zavolokov I.G., Ilyukhina A.Y., Skoromets A.A. Blood test detecting autoantibodies to N-methyl-d-aspartate neuroreceptors for evaluation of patients with transient ischemic attack and stroke. Clin. Chem. 2003, 49:1752-1762.
17. Depoortère R., Dargazanli G., Estenne-Bouhtou G., Coste A., Lanneau C., Desvignes C., Poncelet M., Heaulme M., Santucci V., Decobert M., Cudennec A., Voltz C., Boulay D., Terranova J.P., Stemmelin J., Roger P., Marabout B., Sevrin M., Vigé X., Biton B., Steinberg R., Françon D., Alonso R., Avenet P., Oury-Donat F., Perrault G., Griebel G., George P., Soubrié P., Scatton B Neurochemical, electrophysiological and pharmacological profiles of the selective inhibitor of the glycine transporter-1 SSR504734, a potential new type of antipsychotic. Neuropsychopharmacology 2005, 30:1963-1985.
18. D'Souza D.C., Radhakrishnan R., Perry E., Bhakta S., Singh N.M., Yadav R., Abi-Saab D., Pittman B., Chaturvedi S.K., Sharma M.P., Bell M., Andrade C. Feasibility, safety, and efficacy of the combination of d-serine and computerized cognitive retraining in schizophrenia: an international collaborative pilot study. Neuropsychopharmacology 2013, 38:492-503.
19. Fibiger H.C. Psychiatry, the pharmaceutical industry and the road to better therapeutics. Schizophr. Bull. 2012, 36:649-650.
20. Florance N.R., Davis R.L., Lam C., Szperka C., Zhou L., Ahmad S., Campen C.J., Moss H., Peter N., Gleichman A.J., Glaser C.A., Lynch D.R., Rosenfeld M.R., Dalmau J. Anti-N-methyl-d-aspartate receptor (NMDAR) encephalitis in children and adolescents. Ann. Neurol. 2009, 66:11-18.
21. Gable M.S., Gavali S., Radner A., Tilley D.H., Lee B., Dyner L., Collins A., Dengel A., Dalmau J., Glaser C.A. Anti-NMDA receptor encephalitis: report of ten cases and comparison with viral encephalitis. Eur. J. Clin. Microbiol. Infect. Dis. 2009, 28:1421-1429.
22. Gelfin E., Kaufman Y., Korn-Lubetzki I., Bloch B., Kremer I., Javitt D.C., Heresco-Levy U. d-serine adjuvant treatment alleviates behavioural and motor symptoms in Parkinson's disease. Int. J. Neuropsychopharmacol. 2012, 15:543-549.
23. Goldsmith C.A., Rogers D.P. The case for autoimmunity in the etiology of schizophrenia. Pharmacotherapy 2008, 28:730-741.
24. Granerod, J., Ambrose, H.E., Davies, N.W., Clewley, J.P., Walsh, A.L., Morgan, D., Cunningham, R., Zuckerman, M., Mutton, K.J., Solomon, T., Ward, K.N., Lunn, M.P., Irani, S.R.,Vincent, A., Brown, D.W., Crowcroft, N.S., UK Health Protection Agency (HPA) Aetiology of Encephalitis Study Group, 2010. Causes of encephalitis and differences in their clinical presentations in England: amulticentre, population-based prospective study. Lancet Infect. Dis. 10, 835-844.
25. Graus F., Boronat A., Xifró X., Boix M., Svigelj V., Garcia A., Palomino A., Sabater L., Alberch J., Saiz A. The expanding clinical profile of anti-AMPA receptor encephalitis. Neurology 2010, 74:857-859.
26. Haas D.A., Harper D.G. Ketamine: a review of its pharmacologic properties and use in ambulatory anesthesia. Anesth. Prog. 1992, 39:61-68.
27. Hashimoto K., Fujita Y., Horio M., Kunitachi S., Iyo M., Ferraris D., Tsukamoto T. Co-administration of d-amino acid oxidase inhibitor potentiates the efficacy of d-serine on prepulse inhibition deficits after administration of dizocilpine. Biol. Psychiatry 2009, 65:1103-1106.
28. Heresco-Levy U., Shoham S., Javitt D.C. Glycine site agonists of the N-methyl-d-aspartate receptor and Parkinson's disease: a hypothesis. Mov. Disord. 2013, 28:419-424.
29. Heresco-Levy U., Gelfin G., Bloch B., Levin R., Edelman S., Javitt D.C., Kremer I. A randomized add-on trial of high-dose d-cycloserine for treatment-resistant depression. Int. J. Neuropsychopharmacol. 2013, 16:501-506.
30. Heresco-Levy U., Javitt D.C. Glutamate in Neuropsychiatric Disorders 2008, Research SignPost, Trivandrum, Kerala, India.
31. Heresco-Levy U. Glutamatergic neurotransmission modulators as emerging new drugs for schizophrenia. Expert Opin. Emerg. Drugs 2005, 10:827-844.
32. Heresco-Levy U., Javitt D.C., Ebstein R., Vass A., Lichtenberg P., Bar G., Catinari S., Ermilov M. d-serine efficacy as add-on pharmacotherapy to risperidone and olanzapine for treatment-refractory schizophrenia. Biol. Psychiatry 2005, 57:577-585.
33. Heresco-Levy U., Ermilov M., Lichtenberg P., Bar G., Javitt D.C. High-dose glycine added to olanzapine and risperidone for the treatment of schizophrenia. Biol. Psychiatry 2004, 55:165-171.
34. Heresco-Levy U. Amino acid transmitter systems in schizophrenia and other psychotic disorders. Biological Psychiatry 2002, 587-600. John Wiley & Sons, London. H. D'haenen, J.A. den Boer, M. Westenberg, P. Willner (Eds.).
35. Heresco-Levy U., Javitt D.C., Ermilov M., Mordel C., Silipo G., Lichenstein M. Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia. Arch. Gen. Psychiatry 1999, 56:29-36.
36. Horio M., Fujita Y., Hashimoto K. Therapeutic effects of metabotropic glutamate receptor 5 positive allosteric modulator CDPPB on phencyclidine-induced cognitive deficits in mice. Fundam. Clin. Pharmacol. 2012, [Epub ahead of print]. 10.1111/j.1472-8206.2012.01045.
37. Hughes E.G., Peng X., Gleichman A.J., Lai M., Zhou L., Tsou R., Parsons T.D., Lynch D.R., Dalmau J., Balice-Gordon R.J. Cellular and synaptic mechanisms of anti-NMDA receptor encephalitis. J. Neurosci. 2010, 30:5866-5875.
38. Iizuka T., Sakai F., Ide T., Monzen T., Yoshii S, Iigaya M., Suzuki K., Lynch D.R., Suzuki N., Hata T., Dalmau J. Anti-NMDA receptor encephalitis in Japan: long-term outcome without tumor removal. Neurology 2008, 70:504-511.
39. Irani S.R., Bera K., Waters P., Zuliani L., Maxwell S., Zandi M.S., Friese M.A., Galea I., Kullmann D.M., Beeson D., Lang B., Bien C.G., Vincent A. N-methyl-d-aspartate antibody encephalitis: temporal progression of clinical and paraclinical observations in a predominantly non-paraneoplastic disorder of both sexes. Brain 2010, 133:1655-1667.
40. Ishiura H., Matsuda S., Higashihara M., Hasegawa M., Hida A., Hanajima R., Yamamoto T., Shimizu J., Dalmau J., Tsuji S. Response of anti-NMDA receptor encephalitis without tumor to immunotherapy including rituximab. Neurology 2008, 71:1921-1923.
41. Javitt D.C. Glycine transport inhibitors in the treatment of schizophrenia. Handb. Exp. Pharmacol. 2012, 213:367-399.
42. Javitt D.C., Schoepp D., Kalivas P.W., Volkow N.D., Zarate C., Merchant K., Bear M.F., Umbricht D., Hajos M., Potter W.Z., Lee C.M. Translating glutamate: from pathophysiology to treatment. Sci. Transl. Med. 2011, 3(102):102mr2. 10.1126/scitranslmed.3002804.
43. Javitt D.C., Zukin S.R. Recent advances in the phencyclidine model of schizophrenia. Am. J. Psychiatry 1991, 148:1301-1308.
44. Jones A.L., Mowry B.J., Pender M.P., Greer J.M. Immune dysregulation and self-reactivity in schizophrenia: do some cases of schizophrenia have an autoimmune basis?. Immunol. Cell Biol. 2005, 8:9-17.
45. Kantrowitz J.T., Malhotra A.K., Cornblatt B., Silipo G., Balla A., Suckow R.F., D'Souza C., Saksa J., Woods S.W., Javitt D.C. High dose d-serine in the treatment of schizophrenia. Schizophr. Res. 2010, 121:125-130.
46. Kapur S., Phillips A.G., Insel T.R. Why has it taken so long for biological psychiatry to develop clinical tests and what to do about it?. Mol. Psychiatry 2012, 17:1174-1179.
47. Kayser M.S., Kohler C.G., Dalmau J. Psychiatric manifestations of paraneoplastic disorders. Am. J. Psychiatry 2010, 167:1039-1050.
48. Kemp J.A., Leeson P.D. The glycine site of the NMDA receptor-five years on. Trends Pharmacol. Sci. 1993, 14:20-25.
49. Lai M., Hughes E.G., Peng X., Zhou L., Gleichman A.J., Shu H., Mata S., Kremens D., Vitaliani R., Geschwind M.D., Bataller L., Kalb R.G., Davis R., Graus F, Lynch D.R., Ballice-Gordon R., Dalmau J. AMPA receptor antibodies in limbic encephalitis alter synaptic receptor location. Ann. Neurol. 2009, 65:424-434.
50. Lancaster E., Dalmau J. Neuronal autoantigens--pathogenesis, associated disorders and antibody testing. Nat. Rev. Neurol. 2012, 8:380-390.
51. Lancaster E., Martinez-Hernandez E., Titulaer M.J., Boulos M., Weaver S., Antoine J.C., Liebers E., Kornblum C., Bien C.G., Honnorat J., Wong S., Xu J., Contractor A., Balice-Gordon R., Dalmau J. Antibodies to metabotropic glutamate receptor 5 in the Ophelia syndrome. Neurology 2011, 77:1698-1701.
52. Lane, H.Y., 2011. d-AminoAcid Oxidase Inhibition (DAAOI-1) Add-On Treatment for Chronic Schizophrenia. [Identifier: NCT00960219]. http://www.ClinicalTrials.gov.
53. Lane H.Y., Chang Y.C., Liu Y.C., Chiu C.C., Tsai G.E. Sarcosine or d-serine add-on treatment for acute exacerbation of schizophrenia: a randomized, double-blind, placebo-controlled study. Arch. Gen. Psychiatry 2005, 62:1196-1204.
54. Laurie D.J., Seeburg P.H. Ligand affinities at recombinant N-methyl-d-aspartate receptors depend on subunit composition. Eur. J. Pharmacol. 1994, 268:335-345.
55. Lennox B.R., Coles A.J., Vincent A. Antibody-mediated encephalitis: a treatable cause of schizophrenia. Br. J. Psychiatry 2012, 200:92-94.
56. Leypoldt F., Buchert R., Kleiter I., Marienhagen J., Gelderblom M., Magnus T., Dalmau J., Gerloff C., Lewerenz J. Flurodeoxyglucose positron emission tomography in anti-N-methyl-d-aspartate receptor encephalitis: distinct pattern of disease. J. Neurol. Neurosurg. Psychiatry 2012, 83:681-686.
57. Mat A., Adler H., Merwick A., Chadwick G., Gullo G., Dalmau J.O., Tubridy N. Ophelia syndrome with metabotropic glutamate receptor 5 antibodies in CSF. Neurology 2013, 80:1349-1350.
58. Maeng S., Zarate C.A., Du J., Schloesser R.J., McCammon J., Chen G., Manji H.K. Cellular mechanisms underlying the antidepressant effects of ketamine: role of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors. Biol. Psychiatry 2008, 63:349-352.
59. Malkesman O., Austin D.R., Tragon T., Wang G., Rompala G., Hamidi A.B., Cui Z., Young W.S., Nakazawa K., Zarate C.A., Manji H.K., Chen G. Acute d-serine treatment produces antidepressant-like effects in rodents. Int. J. Neuropsychopharmacol. 2012, 15:1135-1148.
60. Mann A., Machado N.M., Liu N., Mazin A.H., Silver K., Afzal K.I. A multidisciplinary approach to the treatment of anti-NMDA-receptor antibody encephalitis: a case and review of the literature. J. Neuropsychiatry Clin. Neurosci. 2012, 24:247-254.
61. Marco L.A., Joshi R.S. A ketamine-induced rat model of tardive dyskinesia. Prog. Neurobiol. 1992, 38:571-600.
62. Marignier R., Chenevier F., Rogemond V., Sillevis Smitt P., Renoux C., Cavillon G., Androdias G., Vukusic S., Graus F., Honnorat J., Confavreux C. Metabotropic glutamate receptor type 1 autoantibody-associated cerebellitis: a primary autoimmune disease?. Arch. Neurol. 2010, 67:627-630.
63. Masdeu J.C., González-Pinto A., Matute C., Ruiz De Azúa S., Palomino A., De Leon J., Berman K.F., Dalmau J. Serum IgG antibodies against the NR1 subunit of the NMDA receptor not detected in schizophrenia. Am. J. Psychiatry 2012, 169:1120-1121.
64. McCarron N.N., Schulze B.W., Thompson G.A., Conder M.C., Goetz W.A. Acute phencyclidine intoxication: incidence of clinical findings in 1,000 cases. Ann. Emerg. Med. 1981, 10:237-242.
65. Nakanishi S. Metabotropic glutamate receptors. Synaptic transmission, modulation and plasticity. Neuron 1994, 13:1031-1037.
66. Newcomer J.W., Krystal J.H. NMDA receptor regulation of memory and behavior in humans. Hippocampus 2001, 11:529-542.
67. Okamoto S., Hirano T., Takahashi Y., Yamashita T., Uyama E., Uchino M. Paraneoplastic limbic encephalitis caused by ovarian teratoma with autoantibodies to glutamate receptor. Intern. Med. 2007, 46:1019-1022.
68. Olney J.W., Farber N.B. Glutamate receptor dysfunction and schizophrenia. Arch. Gen. Psychiatry 1995, 52:998-1007.
69. Palmer C.L., Cotton L., Henley J.M. The molecular pharmacology and cell biology of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors. Pharmacol. Rev. 2005, 57:253-277.
70. Peery H.E., Day G.S., Dunn S., Fritzler M.J., Prüss H., De Souza C., Doja A., Mossman K., Resch L., Xia C., Sakic B., Belbeck L., Foster W.G. Anti-NMDA receptor encephalitis. The disorder, the diagnosis and the immunobiology. Autoimmun. Rev. 2012, 11:863-872.
71. Peralta V., Campos M.S., de Jalon E.G., Cuesta M.J. DSM-IV catatonia signs and criteria in first-episode drug-naive psychotic patients: psychometric validity and response to antipsychotic medication. Schizophr. Res. 2010, 118:168-175.
72. Prüss H., Höltje M., Maier N., Gomez A., Buchert R., Harms L., Ahnert-Hilger G., Schmitz D., Terborg C., Kopp U., Klingbeil C., Probst C., Kohler S., Schwab J.M., Stoecker W., Dalmau J., Wandinger K.P. IgA NMDA receptor antibodies are markers of synaptic immunity in slow cognitive impairment. Neurology 2012, 78:1743-1753.
73. Rhoads J., Guirgis H., McKnight C., Duchemin A.M. Lack of anti-NMDA receptor autoantibodies in the serum of subjects with schizophrenia. Schizophr. Res. 2011, 129:213-214.
74. Roche Global Web Site, 2010. [Homepage on the Internet]. Phase II Study with First-In-Class Investigation Drug Demonstrates Improvement in Negative Symptoms in Patients With Schizophrenia. Basel. http://www/roche.com/investors/ir_update/inv-update-2010-12-06b.htm.
75. Rogers S.W., Andrews P.I., Gahring L.C., Whisenand T., Cauley K., Crain B., Hughes T.E., Heinemann S.F., McNamara J.O. Autoantibodies to glutamate receptor GluR3 in Rasmussen's encephalitis. Science 1994, 265:648-651.
76. Rosenfeld M.R., Titulaer M., Dalmau J. Paraneoplastic syndromes and autoimmune encephalitis. Five new things. Neurol.: Clin. Pract. 2012, 2:215-223.
77. Rosenfeld M.R., Dalmau J. Anti-NMDA receptor encephalitis and other synaptic autoimmune disorders. Curr. Treat. Options Neurol. 2011, 13:324-332.
78. Sanacora G., Zarate C.A., Krystal J.H., Manji H.K. Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders. Nat. Rev. Drug Discov. 2008, 7:426-437.
79. Sansing L.H., Tüzün E., Ko M.W., Baccon J., Lynch D.R., Dalmau J. A patient with encephalitis associated with NMDA receptor antibodies. Nat. Clin. Pract. Neurol. 2007, 3:291-296.
80. Schmitt S.E., Pargeon K., Frechette E.S., Hirsch L.J., Dalmau J., Friedman D. "Extreme Delta Brush": a unique EEG pattern in adults with anti-NMDA receptor encephalitis. Neurology 2012, 133:1655-1667.
81. Schoepp D.D. Unveiling the functions of presynaptic metabotropic glutamate receptors in the central nervous system. J. Pharmacol. Exp. Ther. 2001, 299:12-20.
82. Sillevis Smitt P., Kinoshita A., De Leeuw B., Moll W., Coesmans M., Jaarsma D., Henzen-Logmans S., Vecht C., De Zeeuw C., Sekiyama N., Nakanishi S., Shigemoto R. Paraneoplastic cerebellar ataxia due to autoantibodies against a glutamate receptor. N. Engl. J. Med. 2000, 342:21-27.
83. Sprengel R. Role of AMPA receptors in synaptic plasticity. Cell Tissue Res. 2006, 326:447-455.
84. Steiner J., Walter M., Glanz W., Sarnyai Z., Bernstein H.G., Vielhaber S., Kästner A., Skalej M., Jordan W., Schiltz K., Klingbeil C., Wandinger K.P., Bogerts B., Stoecker W. Increased prevalence of diverse N-methyl-d-aspartate glutamate receptor antibodies in patients with an initial diagnosis of schizophrenia: specific relevance of IgG NR1a antibodies for distinction from N-methyl-d-aspartate glutamate receptor encephalitis. JAMA Psychiatry 2013, 70:271-278.
85. Suh-Lailam B.B., Haven T.R., Copple S.S., Knapp D., Jaskowski T.D., Tebo A.E. Anti-NMDA-receptor antibody encephalitis: performance evaluation and laboratory experience with the anti-NMDA-receptor IgG assay. Clin. Chim. Acta 2013, 421:1-6.
86. Takahashi Y., Mori H., Mishina M., Watanabe M., Kondo N., Shimomura J., Kubota Y., Matsuda K., Fukushima K., Shiroma N., Akasaka N., Nishida H., Imamura A., Watanabe H., Sugiyama N., Ikezawa M., Fujiwara T. Autoantibodies and cell-mediated autoimmunity to NMDA-type GluRε2 in patients with Rasmussen's encephalitis and chronic progressive epilepsia partialis continua. Epilepsia 2005, 46:152-158.
87. Titulaer M.J., McCracken L., Gabilondo I., Armangué T., Glaser C., Iizuka T., Honig L.S., Benseler S.M., Kawachi I., Martinez-Hernandez E., Aguilar E., Gresa-Arribas N., Ryan-Florance N., Torrents A., Saiz A., Rosenfeld MR., Balice-Gordon R., Graus F., Dalmau J. Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study. Lancet Neurol. 2013, 12:157-165.
88. Tsai G.E., Lin P.Y. Strategies to enhance N-methyl-d-aspartate receptor-mediated neurotransmission in schizophrenia: a critical review and meta-analysis. Curr. Pharm. Des. 2010, 16:522-537.
89. Tsai G., Lane H.Y., Yang P., Chong M.Y., Lange N. Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to antipsychotics for the treatment of schizophrenia. Biol. Psychiatry 2004, 55:452-456.
90. Tsutsui K., Kanbayashi T., Tanaka K., Boku S., Ito W., Tokunaga J., Mori A., Hishikawa Y., Shimizu T., Nishino S. Anti-NMDA receptor antibody detected in encephalitis, schizophrenia, and narcolepsy with psychotic features. BMC Psychiatry 2012, 12:37. 10.1186/1471-244X-12-37.
91. Turner M.R., Irani S.R., Leite M.I., Nithi K., Vincent A., Ansorge O. Progressive encephalomyelitis with rigidity and myoclonus: glycine and NMDA receptor antibodies. Neurology 2011, 77:439-443.
92. van de Riet E.H., Schieveld J.N. First-onset psychosis, anti-NMDAR encephalitis, schizophrenia and consultation-liaison psychiatry. Gen. Hosp. Psychiatry 2013, [Epub ahead of print]. 10.1016/j.genhosppsych.2013.01.014.
93. Vincent A., Bien C.G., Irani S.R., Waters P. Autoantibodies associated with diseases of the CNS: new developments and future challenges. Lancet Neurol. 2011, 10:759-772.
94. Vitaliani R., Mason W., Ances B., Zwerdling T., Jiang Z., Dalmau J. Paraneoplastic encephalitis, psychiatric symptoms and hypoventilation in ovarian teratoma. Ann. Neurol. 2005, 58:594-604.
95. Wandinger K.P., Saschenbrecker S., Stoecker W., Dalmau J. Anti-NMDA-receptor encephalitis: a severe, multistage treatable disorder presenting with psychosis. J. Neuroimmunol. 2011, 231:86-91.
96. Zandi M.S., Irani S.R., Lang B., Waters P., Jones P.B., McKenna P., Coles A.J., Vincent A., Lennox B.R. Disease-relevant autoantibodies in first episode schizophrenia. J. Neurol. 2011, 258:686-688.
97. Zarate C.A., Manji H.K. The promising role of the glutamate system in mood disorders. Glutamate in Neuropsychiatric Disorders 2008, 213-251. Research Signpost, Trivandrum, Kerala, India. U. Heresco-Levy, D.C. Javitt (Eds.).
98. Zuliani L., Graus F., Giometto B., Bien C., Vincent A. Central nervous system neuronal surface antibody associated syndromes: review and guidelines for recognition. J. Neurol. Neurosurg. Psychiatry 2012, 83:638-645.